Spacer
Spacer
Spacer
Spacer

News:

June 10, 2020

Fujifilm to invest 928 million US$ in large scale biologics production

Fujifilm Corporation will invest approximately 100 billion yen (928 million USD) in the Denmark site of Fujifilm Diosynth Biotechnologies, a leading contract development and manufacturing organization (CDMO) for biologics and advanced therapies. According to a press release, the capital investment will double the Denmark site's current drug substance manufacturing capacity, will expand its capabilities to include fill and finish, and enhance its current assembly, labeling and packaging services.


With the investment, the company will expand its production lines for bulk drug substance with the addition of a further six mammalian cell bioreactors, bringing the total to 12 x 20,000-liter bioreactors by fall 2023, making the Denmark facility one of the few major large-scale manufacturing facilities in the bio-CDMO industry. The development will also include the addition of the facility's first fill/finish production line (to be added by summer 2023), featuring a fully-automated, cutting-edge system capable of producing up to approximately 35 million units per year. In spring 2022, a new packaging line equipped with facilities to assemble multiple types of auto-injectors as well as automatic labeling, will also be added.

“Since the acquisition of the Denmark site last year, the facility's strong manufacturing track-record, coupled with Fujifilm Diosynth Biotechnologies' technologies enabling a stable supply of high-quality biopharmaceuticals, has led to new orders not only from existing clients, but also new clients, contributing to our rapid business expansion”, said Takatoshi Ishikawa, executive vice president, general manager of bio-CDMO division, Fujifilm Corporation. “

In August 2019, Fujifilm invested approximately 98 billion yen (890 million US$) to acquire Biogen's manufacturing subsidiary in Denmark, for its world-class cGMP capabilities and its experienced talent.

Fujifilm said it aims to achieve 100 billion yen (928 million US$) in sales in its bio-CDMO business by the fiscal year ending March 2022, and more than double this volume by the fiscal year ending March 2026.

list of current news